Spring Bank Announces Research Agreement with The National Institute of Allergy and Infectious Diseases to Evaluate HBV Antisense Oligonucleotide Compounds
HOPKINTON, Mass. , July 18, 2019 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain can…
Read more